Referans Fiyat ve İlaç Piyasası

1. Aronsson T. et. al. (2001) ―The Impact of Generic Drug Competition on
Brand Name Market Shares—Evidence from Micro Data‖, Review of
Industrial Organization. 19: 425–435.
2. Bergman M. A. and Rudholm N. (2003) ―The Relative Importance of
Actual and Potential Competition: Empirical Evidence from the
Pharmaceuticals Market‖, Journal of Industrial Economics. 51(4): 455–
467.
3. Brekke K. R. et. al. (2009) ―Regulation and Pricing of Pharmaceuticals:
Reference Pricing or Price Cap Regulation‖, European Economic
Review. 53(2): 170-185.
72 Hacettepe Sağlık İdaresi Dergisi, Cilt:11, Sayı:1 (2008)
4. Brekke K. R. et. al. (2007) ―Reference Pricing of Pharmaceuticals‖,
Journal of Health Economics, 26: 613–642.
5. Collier J. and Iheanacho I. (2002) ―The Pharmaceutical Industry as An
Informant‖, The Lancet. 360: 1405-1409.
6. Cutler D. M. and McClellan M. (2001) ―Is Technological Change In
Medicine Worth It?‖, Health Affairs. September-October: 11-29.
7. Danzon P. M. (1999) ‗The Pharmaceutical Industry‘. In B. Bouckaert, G:
deGeest (ed.) The Encyclopedia of Law and Economics. pp: 1055-1091.
www.encyclo.findlaw.com/5880book.pdf.
8. Danzon P. M. and Chao L. W. (2000) ―Does Regulation Drive out
Competition in Pharmaceutical Markets?‖, Journal of Law and
Economics. 43(2): 311-357.
9. Danzon P. M. and Ketcham J. D. (2004) ―Reference Pricing of
Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands,
and New Zealand‖, Forum for Health Economics & Policy. 7: 1-56.
10. Danzon P. M. (2001) ―Reference Pricing: Theory and Evidence‖ In
López-Casasnovas, G., and Jonsson, B. (ed.), Reference Pricing and
Pharmaceutical Policy: Perspectives on Economics and Innovation,
pp: 86-126. Springer, Barcelona.
11. Danzon, P.M. and Liu H. (1996) ―RP and physician drug budgets: The
German Experience in Controlling Pharmaceutical Expenditures",
Working Paper, The Wharton School.
12. Dukes M. N. (2002) ―Accountability of the Pharmaceutical Industry‖,
The Lancet. 360: 1682-1684.
13. Forbes (2008) www.forbes.com
14. Frank R. G. and Salkever D. S. (1997) ―Generic Entry and the Market for
Pharmaceuticals‖, Journal of Economics & Management Strategy. 6:
75–90.
Referans Fiyat ve İlaç Piyasası 73
15. Grabowski H. (2002) Patents, ―Innovation and Access to New
Pharmaceuticals‖, Journal of International Economics Law. 5(4): 849 -860.
16. Grabowski H. and Wang R. (2006) ―The Quantity and Quality of
Worldwide New Drug Introductions: 1982-2003‖, Health Affairs. 25(2):
452-460.
17. Grabowski H. G. and Vernon J. M. (1992) ―Brand Loyalty, Entry, and
Price Competition in Pharmaceuticals after the 1984 Drug Act‖, Journal
of Law and Economics. 35(2): 331-350.
18. Huber M. and Orosz E. (2003) ―Health Expenditure Trends in the OECD
Countries, 1990–2001‖, Health Care Financing Review. 25(1): 1–22
19. Ioannides-Demos L. L. et. al. (2002) ―Reference-based Pricing Schemes:
Effect on Pharmaceutical Expenditure, Resource Utilization and Health
Outcomes‖, PharmacoEconomics. 20(9): 577-591.
20. IMS (2008) IMS Health 2008.
21. Kaló Z. et. al. (2007) ―Does Therapeutic Reference Pricing Always Result
in Cost-Containment? The Hungarian Evidence‖, Health Policy. 80: 402–
412.
22. Kildemoes et. al. (2006) ―The Impact of Population Ageing on Future
Danish Drug Expenditure‖, Health Policy. 75: 298-311.
23. King D. R. and Kanavos P. (2002) ―Encouraging the Use of Generic
Medicines: Implications for Transition Economies‖, Croatian Medical
Journal. 43: 462–469.
24. Lichtenberg F. R. (1996) ―Do (More and Better) Drugs Keep to People
Out of Hospital‖, The American Economic Review. 86(2): 384-388.
25. López-Casasnovas G. and Puig-Junoy J. (2000) ―Review of the Literature
on Reference Pricing‖, Health Policy. Vol. 54: 87–123.
74 Hacettepe Sağlık İdaresi Dergisi, Cilt:11, Sayı:1 (2008)
26. López-Casasnovas G. and Puig-Junoy J. (2005) ―Reference Pricing as a
Pharmaceutical Reimbursement Mechanism‖, The Public Financing of
Pharmaceuticals. In J. Puig-Junoy (ed.), pp: 103-123. Edward Elgar,
Cheltenham.
27. Maynard A. and Bloor, K. (2003) ―Dilemmas in Regulation of the Market
for Pharmaceuticals‖, Health Affairs. 22(3): 1-11.
28. Miller R. D. Jr. and French H. E. (2000) ―Is There a Link Between
Pharmaceutical Consumption and Improved Health in OECD Countries?‖,
Pharmacoeconomics. 18: 33–45.
29. OECD (2008a) Health a Glance 2008, OECD, Paris.
30. OECD (2008b) Pharmaceutical Pricing in a Global Market, OECD,
Paris.
31. Paris V. and Docteur E. (2006) Pharmaceutical Pricing and
Reimbursement Policies in Canada, OECD Health Working Paper No.
24, OECD, Paris.
32. Paris V. and Docteur E. (2008) Pharmaceutical Pricing and
Reimbursement Policies in Germany, OECD Health Working Papers,
No. 39, OECD, Paris.
33. Pavcnik N. (2002) ―Do Pharmaceutical Prices Respond to Potential
Patient Out-of-Pocket Expenses?‖, RAND Journal of Economics. 33 (3):
469–487.
34. Pharmaceutical Pricing and Reimbursement Information (2008) Germany
Pharma Profile, PPRI 2008.
35. Pharmaceutical Research and Manufacturers of America (2005)
Pharmaceutical Industry Profile 2008, Washington, DC.
36. Puig-Junoy J. (2004) ―Incentives and Pharmaceutical Reimbursement
Reforms in Spain‖, Health Policy. 67: 149–165.
Referans Fiyat ve İlaç Piyasası 75
37. Puig-Junoy J. (2007) ―The Impact of Generic Reference Pricing
Interventions in the Statin Market‖, Health Policy. 84: 14-29.
38. Schneeweiss S. (2007) ―Reference Drug Programs: Effectiveness and
Policy Implications‖, Health Policy. 81: 17–28.
39. Simoens S. and Coster De S. (2006a) ―Potential Savings from Increased
Substitution of Generic for Originator Medicines in Europe‖, Journal of
Generic Medicines. 4(1): 43-45.
40. Simoens S. and Coster De S. (2006b) ―Sustaining generic medicines
markets in Europe‖, Journal of Generic Medicines. Vol. 3 (1): 257-268
41. Sood N. et. al. (2009) ―The Effect of Regulation on Pharmaceutical
Revenues: Experience In Nineteen Countries‖, Health Policy. 28(1): 125-137.
42. Zweifel P. and Crivelly L. (1996) ―Price Regulation of Drugs: Lessons
from Germany‖, Journal of Regulatory Economics. 10: 257–273.